佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，1月8日南向资金减持36.9万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金增 持的有4天，累计净增持417.9万股。近20个交易日中，获南向资金增持的有11天，累计净增持254.04万 股。截至目前，南向资金持有佰泽医疗（02609.HK）6539.7万股，占公司已发行普通股的4.96%。 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 证券之星消息，12月22日南向资金增持183.54万股佰泽医疗（02609.HK）。近5个交易日中，获南向资 金增持的有4天，累计净增持403.62万股。近20个交易日中，获南向资金增持的有9天，累计净增持53.46 万股。截至目前，南向资金持有佰泽医疗（02609.HK）6451.08万股，占公司已发行普通股的4.89%。 ...

证券之星消息，12月9日南向资金增持1.02万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金减 持的有1天，累计净减持38.28万股。近20个交易日中，获南向资金减持的有10天，累计净减持200.94万 股。截至目前，南向资金持有佰泽医疗（02609.HK）6247.14万股，占公司已发行普通股的4.73%。 佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - Southbound funds have increased their holdings in Baize Medical (02609.HK) by 103,200 shares on November 20, 2025, indicating a potential positive sentiment towards the company in the market [1]. Summary by Sections Southbound Fund Activity - In the last five trading days, southbound funds have increased their holdings for three days, with a total net increase of 58,200 shares [1]. - Over the past 20 trading days, there have been 12 days of net reductions, totaling 1,262,400 shares [1]. - As of now, southbound funds hold 63,604,200 shares of Baize Medical, accounting for 4.81% of the company's total issued ordinary shares [1]. Shareholding Changes - On November 20, 2025, the total number of shares held was 63,604,200, with a change of 103,200 shares, reflecting a 0.16% increase [2]. - On November 19, 2025, the total was 63,501,000 shares, with a decrease of 150,600 shares, showing a -0.24% change [2]. - On November 18, 2025, the total was 63,651,600 shares, with an increase of 176,400 shares, indicating a 0.28% rise [2]. - On November 17, 2025, the total was 63,475,200 shares, with a decrease of 152,400 shares, reflecting a -0.24% change [2]. - On November 14, 2025, the total was 63,627,600 shares, with an increase of 81,600 shares, showing a 0.13% rise [2]. Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [2]. - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [2]. - Its business encompasses hospital operations, management services, supply of pharmaceuticals, medical devices, consumables, and other related services [2]. - The company also conducts early cancer screening, tumor vaccination, and health management services for potential healthy populations, primarily operating in the Chinese market [2].

Group 1 - The core point of the news is that southbound funds have reduced their holdings in Baize Medical (02609.HK) by 1.62% on October 27, 2025, amounting to a decrease of 106.2 million shares [1][2] - Over the past five trading days, southbound funds have reduced their holdings for four days, with a total net reduction of 257.4 million shares [1][2] - As of now, southbound funds hold 64.476 million shares of Baize Medical, representing 4.88% of the company's total issued ordinary shares [1][2] Group 2 - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [2] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [2] - Its business operations include hospital services, hospital management services, supply of pharmaceuticals, medical devices, and consumables, as well as other health management services [2]

Core Insights - Southbound funds reduced their holdings in Baize Medical (02609.HK) by 1.7418 million shares on October 22, 2025, marking a decrease of 2.61% [1][2] - Over the past five trading days, there were four days of reductions, totaling a net decrease of 2.274 million shares [1] - In the last twenty trading days, southbound funds increased their holdings on twelve occasions, with a cumulative net increase of 45.6066 million shares [1] Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [2] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [2] - Its business operations encompass hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [2] - The company conducts cancer diagnosis, treatment, rehabilitation, and end-of-life care for patients, as well as early cancer screening, cancer vaccination, and health management services for other potential health populations [2] - Baize Medical primarily operates in the Chinese market [2]

Core Insights - Southbound funds increased their holdings in Baize Medical (02609.HK) by 384,600 shares on October 15, 2025, marking a net increase of 2,892,600 shares over the last five trading days [1] - Over the past 20 trading days, Baize Medical has seen a total net increase of 67,140,600 shares from southbound funds, with 16 days of net buying activity [1] - As of now, southbound funds hold 67,140,600 shares of Baize Medical, representing 5.08% of the company's total issued ordinary shares [1] Trading Data Summary - On October 15, 2025, total shares held reached 67,140,600 with a change of 384,600 shares, reflecting a 0.58% increase [2] - On October 14, 2025, total shares held were 66,756,000 with a change of 180,000 shares, a 0.27% increase [2] - On October 13, 2025, total shares held were 66,576,000 with a change of 897,600 shares, a 1.37% increase [2] - On October 3, 2025, total shares held were 65,678,400 with a change of 1,597,200 shares, a 2.49% increase [2] - On October 2, 2025, total shares held were 64,081,200 with a change of -166,800 shares, a -0.26% decrease [2] Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [2] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [2] - Key business areas include hospital operations, hospital management services, supply of pharmaceuticals, medical devices, and consumables [2] - Services provided encompass cancer diagnosis, treatment, rehabilitation, and end-of-life care, as well as early cancer screening, cancer vaccination, and health management for other potential health populations [2] - The company primarily operates in the Chinese market [2]

Core Viewpoint - The sudden surge in the stock price of Baize Medical (02609.HK) is attributed to its inclusion in the Hong Kong Stock Connect program, which has significantly increased its liquidity and market attention, despite the company's underwhelming financial performance [2][4][5]. Group 1: Stock Performance - On September 16, Baize Medical's stock price soared over 90% at one point, closing up 28.03% at HKD 13.11 per share, with a market capitalization of approximately HKD 17.29 billion [2]. - The stock has seen a nearly 100% increase over two days, with trading volume reaching nearly HKD 8 billion and a high turnover rate [4]. - The stock's recent performance is part of a broader trend, as other newly listed medical stocks like Yaojie Ankang-B (02617.HK) and Mirxes-B (02629.HK) have also experienced significant price increases [6]. Group 2: Company Background - Baize Medical is a leading domestic oncology specialty medical service provider, offering comprehensive cancer care services, including screening, diagnosis, treatment, and rehabilitation, with operations in five provinces [4]. - The company went public on the Hong Kong Stock Exchange in June 2023, but its stock performance was initially lackluster before the recent surge [4]. Group 3: Financial Performance - For the years 2022 to 2024, Baize Medical's projected revenues are RMB 803 million, RMB 1.072 billion, and RMB 1.189 billion, respectively, while it is expected to incur losses of RMB 75.515 million, RMB 24.406 million, and RMB 3.557 million during the same period [5]. - In the first half of this year, the company reported revenue of RMB 575 million, a slight increase of 0.66% year-on-year, but the loss for the period was RMB 20.262 million, significantly widening compared to the previous year [6]. - As of June 30, 2025, Baize Medical's goodwill reached RMB 643 million, primarily due to acquisitions, which poses a risk of impairment affecting its financial health [6].

Core Viewpoint - Baize Medical (02609) has seen a significant stock price increase of over 50%, reaching a new high of 17.06 HKD, with a cumulative rise of 130% over the past two trading days [1] Company Summary - As of the latest report, Baize Medical's stock price increased by 58.01%, trading at 16.19 HKD, with a trading volume of 1.437 billion HKD and a total market capitalization exceeding 20 billion HKD [1] - The company has been included in the Hong Kong Stock Connect list, effective from September 8, which has contributed to the increased trading activity [1] - Baize Medical operates in the "full-cycle cancer medical services" sector, providing services such as screening, diagnosis, treatment, and rehabilitation [1] - The company has successfully operated eight hospitals across five provinces and cities, including Beijing, Tianjin, Anhui, Shanxi, and Henan [1] - In the first half of the year, Baize Medical reported revenue of 575 million RMB, a year-on-year increase of 0.66%, while the loss attributable to shareholders widened to 27.62 million RMB, an increase of 139.18% year-on-year [1]

Core Viewpoint - Baize Medical (02609) has seen a significant stock price increase of over 50%, reaching a new high of 17.06 HKD, with a cumulative rise of 130% over the past two trading days [1] Company Summary - Baize Medical is a service provider in the "full-cycle medical services for tumors" sector, offering services such as screening, diagnosis, treatment, and rehabilitation [1] - The company has successfully operated eight hospitals across five provinces and cities, including Beijing, Tianjin, Anhui, Shanxi, and Henan [1] - In the first half of the year, Baize Medical reported a revenue of 575 million RMB, reflecting a year-on-year increase of 0.66% [1] - The company experienced a shareholder loss of 27.62 million RMB, which represents a year-on-year increase of 139.18% in losses [1] Market Activity - The stock price of Baize Medical has surged by 58.01% to 16.19 HKD, with a trading volume of 1.437 billion HKD, and the total market capitalization has surpassed 20 billion HKD [1] - The company has been included in the Hong Kong Stock Connect list, effective from September 8, which has contributed to the increased trading activity [1] - The current percentage of Baize Medical shares held through the Hong Kong Stock Connect is 0.21% [1]